Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Evaluating the Safety and Effectiveness of Evolving Opioid Agonist Therapy Prescribing Patterns
EF 2022-23
Résumé
Canada's opioid-related deaths epidemic is a growing public health emergency, claiming 29,000 lives since 2016. Although early in the overdose epidemic, prescription opioids were commonly implicated in fatal overdoses, the emergence of fentanyl in Canada's unregulated drug supply has led to a shift in the drivers of opioid-related harms. Specifically, in 2021 fentanyl was detected in 92% of opioid-related deaths across Ontario. Given fentanyl's high potency, people with opioid use disorder often report dissatisfaction with traditional first line opioid agonist therapy (OAT), placing them at increased risk of harm following treatment discontinuation. This shift in Canada's opioid landscape has led to the introduction of new treatment approaches for opioid use disorder, including recommendations for the use of high dose methadone, combination therapy with methadone and slow-release oral morphine, and newer formulations of buprenorphine. However, real-world evidence surrounding the harms and benefits of these new approaches is currently lacking. Using data on all hospital admissions, emergency department visits, prescriptions dispensed from retail pharmacies, and opioid-related deaths in the province of Ontario, Canada, I propose a body of work that will describe evolution of prescribing patterns for OAT and evaluate the impact of these new treatment approaches on patient care outcomes. My work will be used to inform optimal medication management for opioid use disorder in the context of the fentanyl-era, revise therapeutic guidelines and guide clinical decision-making. Findings will also be used by drug-policy decision makers in Ontario and across Canada, to inform future policy development and refinement, with the aim of reducing the number of lives lost to Canada's toxic drug supply.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
475670
Name
Garg Ria
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Health Services and Policy Research
Theme2
Social / Cultural / Environmental / Population Health
Prcname2
Doctoral Research Awards - B
Projecttitle
Evaluating the Safety and Effectiveness of Evolving Opioid Agonist Therapy Prescribing Patterns
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Comparative Drug Safety; Epidemiologic Methods; Opioid Use Disorder; Pharmacoepidemiology; Pharmacovigilance
Abstract
Canada's opioid-related deaths epidemic is a growing public health emergency, claiming 29,000 lives since 2016. Although early in the overdose epidemic, prescription opioids were commonly implicated in fatal overdoses, the emergence of fentanyl in Canada's unregulated drug supply has led to a shift in the drivers of opioid-related harms. Specifically, in 2021 fentanyl was detected in 92% of opioid-related deaths across Ontario. Given fentanyl's high potency, people with opioid use disorder often report dissatisfaction with traditional first line opioid agonist therapy (OAT), placing them at increased risk of harm following treatment discontinuation. This shift in Canada's opioid landscape has led to the introduction of new treatment approaches for opioid use disorder, including recommendations for the use of high dose methadone, combination therapy with methadone and slow-release oral morphine, and newer formulations of buprenorphine. However, real-world evidence surrounding the harms and benefits of these new approaches is currently lacking. Using data on all hospital admissions, emergency department visits, prescriptions dispensed from retail pharmacies, and opioid-related deaths in the province of Ontario, Canada, I propose a body of work that will describe evolution of prescribing patterns for OAT and evaluate the impact of these new treatment approaches on patient care outcomes. My work will be used to inform optimal medication management for opioid use disorder in the context of the fentanyl-era, revise therapeutic guidelines and guide clinical decision-making. Findings will also be used by drug-policy decision makers in Ontario and across Canada, to inform future policy development and refinement, with the aim of reducing the number of lives lost to Canada's toxic drug supply.
Competitiondate
202211
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Garg, Ria
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~